Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1878 2
1882 1
1895 1
1944 1
1945 1
1947 2
1948 1
1950 2
1951 1
1952 3
1953 3
1954 3
1955 2
1956 2
1957 1
1958 4
1959 2
1960 4
1961 5
1962 8
1963 12
1964 30
1965 13
1966 21
1967 31
1968 40
1969 46
1970 39
1971 48
1972 34
1973 45
1974 44
1975 58
1976 57
1977 53
1978 49
1979 63
1980 51
1981 35
1982 39
1983 31
1984 27
1985 58
1986 36
1987 42
1988 40
1989 47
1990 44
1991 41
1992 37
1993 37
1994 45
1995 41
1996 40
1997 48
1998 57
1999 41
2000 52
2001 34
2002 31
2003 38
2004 37
2005 44
2006 46
2007 34
2008 30
2009 30
2010 28
2011 27
2012 29
2013 35
2014 27
2015 27
2016 21
2017 31
2018 37
2019 36
2020 33
2021 28
2022 39
2023 32
2024 14

Text availability

Article attribute

Article type

Publication date

Search Results

2,315 results

Results by year

Filters applied: . Clear all
Page 1
Safety and Efficacy of AGN-190584 in Individuals With Presbyopia: The GEMINI 1 Phase 3 Randomized Clinical Trial.
Waring GO 4th, Price FW Jr, Wirta D, McCabe C, Moshirfar M, Guo Q, Gore A, Liu H, Safyan E, Robinson MR. Waring GO 4th, et al. JAMA Ophthalmol. 2022 Apr 1;140(4):363-371. doi: 10.1001/jamaophthalmol.2022.0059. JAMA Ophthalmol. 2022. PMID: 35238902 Free PMC article. Clinical Trial.
IMPORTANCE: AGN-190584 (Allergan, an AbbVie company) is an optimized topical formulation of pilocarpine hydrochloride, 1.25%, designed for managing presbyopia and enhanced with a proprietary vehicle. ...AGN-190584 is a safe and efficaciou …
IMPORTANCE: AGN-190584 (Allergan, an AbbVie company) is an optimized topical formulation of pilocarpine hydrochloride, …
Pilocarpine 1.25% and the changing landscape of presbyopia treatment.
Meghpara BB, Lee JK, Rapuano CJ, Mian SI, Ho AC. Meghpara BB, et al. Curr Opin Ophthalmol. 2022 Jul 1;33(4):269-274. doi: 10.1097/ICU.0000000000000864. Curr Opin Ophthalmol. 2022. PMID: 35779051 Review.
PURPOSE OF REVIEW: Despite affecting approximately 1.8 billion individuals worldwide, until recently, a pharmacologic treatment for presbyopia was not available. This special commentary reviews the treatment of presbyopia with a focus on the recently approved medica …
PURPOSE OF REVIEW: Despite affecting approximately 1.8 billion individuals worldwide, until recently, a pharmacologic treatment for presb …
Safety and Efficacy of Twice-Daily Pilocarpine HCl in Presbyopia: The Virgo Phase 3, Randomized, Double-Masked, Controlled Study.
Kannarr S, El-Harazi SM, Moshirfar M, Lievens C, Kim JL, Peace JH, Safyan E, Liu H, Zheng S, Robinson MR. Kannarr S, et al. Am J Ophthalmol. 2023 Sep;253:189-200. doi: 10.1016/j.ajo.2023.05.008. Epub 2023 May 5. Am J Ophthalmol. 2023. PMID: 37149245 Free article. Clinical Trial.
PURPOSE: To evaluate the safety, efficacy, and pharmacokinetics of pilocarpine hydrochloride 1.25% (Pilo hereafter) compared with vehicle when administered bilaterally, twice daily (6 hours apart) for 14 days in participants with presbyopia. ...Key safety measures i …
PURPOSE: To evaluate the safety, efficacy, and pharmacokinetics of pilocarpine hydrochloride 1.25% (Pilo hereafter) compared with veh …
Effects of topical pilocarpine on ocular growth and refractive development in rabbits.
Tong L, Cui D, Zeng J. Tong L, et al. Eur J Ophthalmol. 2021 Jul;31(4):2107-2115. doi: 10.1177/1120672120934962. Epub 2020 Jun 11. Eur J Ophthalmol. 2021. PMID: 32524847
METHODS: Twenty three-week-old New Zealand white rabbits were treated with 0.5% pilocarpine in the right eye for 6 weeks. The left eyes served as contralateral controls. ...These changes raise the possibility that pilocarpine may promote axial elongati …
METHODS: Twenty three-week-old New Zealand white rabbits were treated with 0.5% pilocarpine in the right eye for 6 weeks. The …
Pigment release.
Mapstone R. Mapstone R. Br J Ophthalmol. 1981 Apr;65(4):258-63. doi: 10.1136/bjo.65.4.258. Br J Ophthalmol. 1981. PMID: 7236570 Free PMC article.
Guttae phenylephrine 10% produced a significant decrease in intraocular pressure and increase in facility of outflow in eyes with untreated ocular hypertension. If at the same time pigment was released into the aqueous, the pressure and outflow effect was nullified. …
Guttae phenylephrine 10% produced a significant decrease in intraocular pressure and increase in facility of outflow in eyes with unt …
Vitreofoveal Traction Associated With Pilocarpine for Presbyopia.
Amarikwa L, Michalak SM, Caul S, Mruthyunjaya P, Rahimy E. Amarikwa L, et al. Ophthalmic Surg Lasers Imaging Retina. 2022 Jul;53(7):410-411. doi: 10.3928/23258160-20220629-01. Epub 2022 Jul 1. Ophthalmic Surg Lasers Imaging Retina. 2022. PMID: 35858231
Vuity (pilocarpine HCL ophthalmic 1.25%) was approved for the treatment of presbyopia in October 2021. Previous case series have reported the presence of vitreofoveal traction and retinal detachment following pilocarpine administration, but this was no …
Vuity (pilocarpine HCL ophthalmic 1.25%) was approved for the treatment of presbyopia in October 2021. Previous case se …
Pilocarpine 1.25% for the treatment of presbyopia.
Mansoori T. Mansoori T. Indian J Ophthalmol. 2023 Jan;71(1):308-309. doi: 10.4103/ijo.IJO_1901_22. Indian J Ophthalmol. 2023. PMID: 36588262 Free PMC article. No abstract available.
Comparison study between pilocarpine and tropicamide drops on corneal topography and their effect on IL-6 and TNF-alpha levels in tear.
Zhang Y, Zhao J. Zhang Y, et al. Cell Mol Biol (Noisy-le-grand). 2022 Jun 30;68(6):73-78. doi: 10.14715/cmb/2022.68.6.12. Cell Mol Biol (Noisy-le-grand). 2022. PMID: 36227674
On the other hand, different factors (such as contact lens wear, ocular surface disorders, trauma, dry eye, and immunosuppression) could alter the immune defense mechanisms of the outer eye and permit microorganisms to invade the cornea. ...The other eye …
On the other hand, different factors (such as contact lens wear, ocular surface disorders, trauma, dry eye, and immunosuppress …
2,315 results